Pulmonary Embolism Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The pulmonary embolism clinical trial market research report provides an overview of the pulmonary embolism clinical trials scenario. The report provides top-line data relating to the clinical trials on pulmonary embolism. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Pulmonary Embolism Clinical Trials Market by Segmentation Regions and Countries
The key regions in the pulmonary embolism clinical trials market are Middle East & Africa, Asia-Pacific, Europe, North America, and South & Central America, in which, Europe leads the market.
In a country-wise analysis, as of October 2022, China has the highest number of pulmonary embolism clinical trials, followed by Russia, the US, Germany, Canada, France, Thailand, Italy, Netherlands, and Spain.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Canada has the highest proportion of pulmonary embolism to cardiovascular clinical trials. Moreover, out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of pulmonary embolism to cardiovascular clinical trials. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Pulmonary Embolism Clinical Trials Analysis by Regions
For more regional insights into the Pulmonary Embolism clinical trials market, download a free report sample
Pulmonary Embolism Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the pulmonary embolism clinical trials market are institution, company, and the government. Out of them, company dominates the market.
Pulmonary Embolism Clinical Trials Market Analysis by Sponsor Types
For more sponsor type insights into the Pulmonary Embolism clinical trials market, download a free report sample
Pulmonary Embolism Clinical Trials Market - Competitive Landscape
The leading sponsors in the pulmonary embolism clinical trials market are Bayer AG, C. H. Boehringer Sohn AG & Co KG, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Daiichi Sankyo Co Ltd, Bio-Innova & Synchron Co Ltd, GSK plc, Novartis AG, and International Bio Service Co Ltd. Out of them, Bayer AG has conducted the highest number of pulmonary embolism clinical trials.
Pulmonary Embolism Clinical Trials Market Analysis by Sponsors
To know more about the leading players in the Pulmonary Embolism clinical trials market, download a free report sample
Pulmonary Embolism Clinical Trials Market Report Overview
Key Regions | Middle East & Africa, Asia-Pacific, Europe, North America, and South & Central America |
Key Countries | China, Russia, the US, Germany, Canada, France, Thailand, Italy, Netherlands, and Spain |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Bayer AG, C. H. Boehringer Sohn AG & Co KG, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Daiichi Sankyo Co Ltd, Bio-Innova & Synchron Co Ltd, GSK plc, Novartis AG, and International Bio Service Co Ltd |
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies concerning investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
C. H. Boehringer Sohn AG & Co KG
Bristol-Myers Squibb Co
Johnson & Johnson
Pfizer Inc
Daiichi Sankyo Co Ltd
Bio-Innova & Synchron Co Ltd
GSK plc
Novartis AG
International Bio Service Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the pulmonary embolism clinical trials market?
The key regions in the pulmonary embolism clinical trials market are Middle East & Africa, Asia-Pacific, Europe, North America, and South & Central America.
-
What are the key countries in the pulmonary embolism clinical trials market?
The key countries in the pulmonary embolism clinical trials market are China, Russia, the US, Germany, Canada, France, Thailand, Italy, Netherlands, and Spain.
-
What are the key sponsor types in the pulmonary embolism clinical trials market?
The key sponsor types in the pulmonary embolism clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the pulmonary embolism clinical trials market?
The leading sponsors in the pulmonary embolism clinical trials market are Bayer AG, C. H. Boehringer Sohn AG & Co KG, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Daiichi Sankyo Co Ltd, Bio-Innova & Synchron Co Ltd, GSK plc, Novartis AG, and International Bio Service Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.